• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Enanta Pharmaceuticals Inc

+ Add to Watchlist


42.3900 USD 1.2500 3.04%

As of 16:30:00 ET on 12/17/2014.

Snapshot for Enanta Pharmaceuticals Inc (ENTA)

Open: 41.0400 Day's Range: 40.5600 - 42.6700 Volume: 323,592
Previous Close: 41.1400 52wk Range: 27.0000 - 49.0900 1-Yr Rtn: +19.04%

Stock Chart for ENTA

No chart data available.
  • ENTA:US 42.3900
  • 1D
  • 1M
  • 1Y
Interactive ENTA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ENTA

Current P/E Ratio (ttm) 24.0852
Estimated P/E(09/2015) 5.0724
Relative P/E vs. SPX 1.4591
Earnings Per Share (USD) (ttm) 1.7600
Est. EPS (USD) (09/2015) 8.3570
Est. PEG Ratio -
Market Cap (M USD) 788.63
Shares Outstanding (M) 18.60
30 Day Average Volume 322,590
Price/Book (mrq) 5.3024
Price/Sale (ttm) 16.4380
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ENTA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ENTA

Enanta Pharmaceuticals, Inc. manufactures pharmaceutical products. The Company develops, produces, and markets antibacterial drugs for hepatitis C virus, respiratory tract infections, intravenous, and oral treatments for hospitals and communities. Enanta Pharmaceuticals offers its products throughout the United States.

Jay R LulyPresident/CEONathaniel S Gardiner "Nat"Senior VP/General Counsel
Paul J MellettSenior VP:Finance/CFOTimothy D OcainSenior VP:New Product Strategy
More Company Profile & Key Executives for ENTA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil